Horm Metab Res 2020; 52(10): 742-746
DOI: 10.1055/a-1099-9556
Endocrine Research

Acute Statin Administration Reduces Levels of Steroid Hormone Precursors

Edra London
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA
,
Christina Tatsi
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA
,
Steven J. Soldin
2   Department of Laboratory Medicine, NIH, Bethesda, Maryland, USA
,
Christopher A. Wassif
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA
,
Peter Backlund
3   Biomedical Mass Spectrometry Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA
,
David Ng
4   Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA
,
Leslie G. Biesecker
4   Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA
,
Constantine A. Stratakis
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA
› Institutsangaben
Funding This research was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Intramural Research Program.

Abstract

Cholesterol-lowering statin drugs are used by approximately 25% of US adults 45 years of age and older and frequency of use is even higher among the elderly. Cholesterol provides the substrate for steroid hormone synthesis and its intracellular concentrations are tightly regulated. Our aim was to evaluate whether statin use acutely changes the circulating levels of cortisol, other glucocorticoid precursor molecules and their metabolites. Fourteen subjects not taking statins were administered a single oral dose (2 mg) of pitavastatin. Blood samples collected at baseline and 24 h post-treatment were analyzed for plasma cholesterol and steroid hormone profile. A parallel study in mice entailed the administration of atorvastatin (10 mg/kg) via orogastric delivery for three consecutive days. Cholesterol and corticosterone levels were quantified at baseline and at 1-day and 1-week post-treatment. Several precursor molecules in the steroidogenic pathway (corticosterone, cortisone, and 11-deoxycortisol) were significantly decreased 24 h after administration of a single dose of pitavastatin in human study subjects. Their circulating cholesterol concentrations were unchanged. In mice, there were no significant differences in serum cholesterol or corticosterone at 1-day or 1-week post-treatment compared to both pre-treatment baseline levels and control group levels. We conclude that acute dysregulation of the production of certain glucocorticoid precursor molecules was observed after a single treatment with a lipophilic statin drug. This may be of clinical relevance for individuals with underlying or subclinical adrenal insufficiency.



Publikationsverlauf

Eingereicht: 12. August 2019

Angenommen: 09. Januar 2020

Artikel online veröffentlicht:
10. Februar 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011; 32: 81-151
  • 2 Mason JI, Rainey WE. Steroidogenesis in the human fetal adrenal: A role for cholesterol synthesized de novo. J Clin Endocrinol Metab 1987; 64: 140-147
  • 3 Gwynne JT, Strauss JF. The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands. Endocr Rev 1982; 3: 299-329
  • 4 Miller WL, Bose HS. Early steps in steroidogenesis: Intracellular cholesterol trafficking. J Lipid Res 2011; 52: 2111-2135
  • 5 Prihoda JS, Pappu AS, Smith FE. et al. The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab 1991; 72: 567-574
  • 6 Mol MJ, Stalenhoef AF, Stuyt PM. et al. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin Endocrinol (Oxf) 1989; 31: 679-689
  • 7 Candrina R, Balestrieri G, Salvi A. et al. Cortisol secretion in patients on simvastatin. Lancet 1990; 335: 53
  • 8 Stone NJ, Robinson JG, Lichtenstein AH. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (Suppl. 02) S1-S45
  • 9 Johansen ME, Green LA, Sen A. et al. Cardiovascular risk and statin use in the United States. Ann Fam Med 2014; 12: 215-223
  • 10 Collins R, Reith C, Emberson J. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561
  • 11 Straube R, Mϋller G, Voit-Bak K. et al. Metabolic and non-metabolic peripheral neuropathy: Is there a place for therapeutic apheresis?. Horm Metab Res 2019; 51: 779-784
  • 12 Tsentidis C, Bampilis A, Ntova V. et al. Metabolic syndrome as a predictor of adrenal functional status: A discriminant multivariate analysis versus logistic regression analysis. Horm Metab Res 2019; 51: 47-53
  • 13 Mintziori G, Georgiou T, Analgnostis P. et al. Could lipid profile be used as a marker of autonomous cortisol secretion in patients with adrenal incidentalomas?. Horm Metab Res 2018; 50: 551-555
  • 14 Straube R, Boit-bak K, Gor A. et al. Lipid profiles in lyme borreliosis: A potential role for apheresis?. Horm Metab Res 2019; 51: 326-329
  • 15 Hanefeld M, Schaper F, Appelt D. et al. Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk. Horm Metab Res 2011; 43: 980-983
  • 16 Stolze BR, Gounden V, Gu J. et al. An improved micro-method for the measurement of steroid profiles by APPI-LC-MS/MS and its use in assessing diurnal effects on steroid concentrations and optimizing the diagnosis and treatment of adrenal insufficiency and CAH. J Steroid Biochem Mol Biol 2016; 162: 110-116
  • 17 Kelley RI. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. Clin Chim Acta 1995; 236: 45-58
  • 18 Parikh TP, Stolze B, Ozarda Y. et al. Diurnal variation of steroid hormones and reference intervals using mass spectrometric analysis. Endocr Connect 2018; 7: 1354-1361
  • 19 Illingworth DR, Kenny TA, Orwoll ES. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab 1982; 54: 27-33
  • 20 Laue L, Hoeg JM, Barnes K. et al. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway. J Clin Endocrinol Metab 1987; 64: 531-535
  • 21 Antonopoulos AS, Margaritis M, Lee R. et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18: 1519-1530
  • 22 Kanat M, Serin E, Tunckale A. et al. A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study). J Endocrinol Invest 2009; 32: 852-856
  • 23 Ormiston T, Wolkowitz OM, Reus VI. et al. Hormonal changes with cholesterol reduction: A double-blind pilot study. J Clin Pharm Ther 2004; 29: 71-73
  • 24 Bernini GP, Brogi G, Arngenio GF. et al. Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients. J Endocrinol Invest 1998; 21: 310-317
  • 25 Sahebkar A, Rathouska J, Simental-Mendia LE. et al. Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 2016; 103: 17-25
  • 26 Munkboel CH, Baake MLK, Styrishave B. Atorvastatin decreases steroid production in H295R cells and in major endocrine tissues of male rats. Arch Toxicol 2018; 92: 1703-1715
  • 27 Lim CT, Koob B. Normal Physiology of ACTH and GH Release in the Hypothalamus and Anterior Pituitary in Man. Endotext [Internet]. 2017. South Dartmouth (MA): MDText.com, Inc.; 2000, Oct 24, 2017
  • 28 Baudrand R, Pojoga LH, Vaidya A. et al. Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. Circulation 2015; 132: 1825-1833
  • 29 London E, Wassif CA, Horvath A. et al. Cholesterol biosynthesis and trafficking in cortisol-producing lesions of the adrenal cortex. J Clin Endocrinol Metab 2015; 100: 3660-3667
  • 30 Oluleye OW, Kronmal RA, Folsom AR. et al. Association between statin use and sex hormone in the multi-ethnic study of atherosclerosis cohort. J Clin Endocrinol Metab 2019; 104: 4600-4606
  • 31 Dobs AS, Schrott H, Davidson MH. et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000; 49: 1234-1238
  • 32 Dobs AS, Miller S, Neri G. et al. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 2000; 49: 115-121
  • 33 Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 1993; 42: 1146-1152
  • 34 Mastroberardino G, Costa C, Gavelli MS. et al. Plasma cortisol and testosterone in hypercholesterolaemia treated with clofibrate and lovastatin. J Int Med Res 1989; 17: 388-394
  • 35 Bohm M, Herrmann W, Wassmann S. et al. Does statin therapy influence steroid hormone synthesis?. Z Kardiol 2004; 93: 43-48
  • 36 Farnsworth WH, Hoeg JM, Maher M. et al. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J Clin Endocrinol Metab 1987; 65: 546-550
  • 37 Hall SA, Page ST, Travison TG. et al. Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007; 16: 1587-1594
  • 38 Mondul AM, Selvin E, Rohrmann S. et al. Association of serum cholesterol and cholesterol-lowering drug use with serum sex steroid hormones in men in NHANES III. Cancer Causes Control 2010; 21: 1575-1583
  • 39 Bairey Merz CN, Olson MB, Johnson BD. et al. Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: The Women's Ischemia Syndrome Evaluation (WISE). Am J Med 2002; 113: 723-727
  • 40 Camus MC, Chapman MJ, Forgez P. et al. Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus. J Lipid Res 1983; 24: 1210-1228